R&D News | pharmaphorum

News

Sanofi drops lung cancer ADC tusamitamab ravtansine

French drugmaker Sanofi has halted the development of its antibody-drug conjugate (ADC) tusamitamab ravtansine after the drug failed a phase 3 trial in non-small cell lung

News

GSK taps Hansoh for another cancer ADC candidate

GSK has turned to China’s Hansoh Pharma to add another antibody-drug conjugate (ADC) to its oncology pipeline, this time licensing a B7-H3-targeting candidate for $185 million upfront

News

Argenx dealt another blow as Vyvgart Hytrulo fails again

Shares in Argenx have been taking a bashing this morning after the company announced its new subcutaneous formulation of Vyvgart had missed the mark in another phase 3 tri

News

Aclaris slashes staff as it trims its pipeline

Aclaris Therapeutics has said it will cut 46% of its workforce after deciding to discontinue the development of lead drug zunsemetinib (ATI-450) for immuno-inflammatory in

News

Novo Nordisk Foundation puts $260m into vaccine drive

The Novo Nordisk Foundation (NNF) is funding a major new R&D initiative in the area of respiratory infections, with up to DKK 1.8 billion ($260 million) earmarked for

News

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

GSK has said that a regimen of PD-1 inhibitor Jemperli with PARP inhibitor Zejula has shown efficacy in the second stage of the RUBY trial, which could open up wider use i

Sanofi drops lung cancer ADC tusamitamab ravtansine

GSK taps Hansoh for another cancer ADC candidate

Argenx dealt another blow as Vyvgart Hytrulo fails again

Aclaris slashes staff as it trims its pipeline

Novo Nordisk Foundation puts $260m into vaccine drive

New RUBY readout buoys GSK’s Jemperli in endometrial cancer

The long-delayed promise of the microbiome, with Sam Possemi...

How to meet your physicians where they are online

News

Editor's Picks